<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://pharmadevicenews.com/gene-editing-can-nearly-eliminate-sickle-cell-crises-a-daily-pill-may-still-reach-far-more-patients/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T04:58:20+00:00</news:publication_date>
      <news:title>Gene editing can nearly eliminate sickle cell crises. A daily pill may still reach far more patients</news:title>
      <news:keywords>Agios Pharmaceuticals, Casgevy, Etavopivat, HIBISCUS, LYFGENIA, mitapivat, Novo Nordisk, sickle cell disease, Vertex Pharmaceuticals</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-tablets-generic-e1788149113473.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/cagrisema-delivered-25-weight-loss-in-early-responders-what-does-that-reveal-about-novo-nordisks-obesity-drug/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T04:53:45+00:00</news:publication_date>
      <news:title>CagriSema delivered 25% weight loss in early responders. What does that reveal about Novo Nordisk’s obesity drug?</news:title>
      <news:keywords>cagrilintide, CagriSema, Novo Nordisk, ObesityWeek, REDEFINE 1, REDEFINE 9, semaglutide, United States Food and Drug Administration</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2025/12/oral-weight-loss-medication.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/amylyx-cut-post-bariatric-hypoglycaemia-events-by-55-could-avexitide-become-the-first-approved-treatment/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T03:52:56+00:00</news:publication_date>
      <news:title>Amylyx cut post-bariatric hypoglycaemia events by 55%. Could avexitide become the first approved treatment?</news:title>
      <news:keywords>Amylyx Pharmaceuticals, Avexitide, LUCIDITY, ObesityWeek, Stanford University, United States Food and Drug Administration</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/vedabio-detected-respiratory-targets-in-under-10-minutes-could-crispr-bypass-pcrs-biggest-bottleneck/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T03:49:30+00:00</news:publication_date>
      <news:title>VedaBio detected respiratory targets in under 10 minutes. Could CRISPR bypass PCR’s biggest bottleneck?</news:title>
      <news:keywords>Association for Molecular Pathology, Mammoth Biosciences, San Diego, Seattle, Siemens Healthineers, UCP Merchant Medicine, VedaBio</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/ivonescimab-delayed-lung-cancer-progression-why-did-the-fda-still-reject-summits-application/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T03:44:39+00:00</news:publication_date>
      <news:title>Ivonescimab delayed lung cancer progression. Why did the FDA still reject Summit’s application?</news:title>
      <news:keywords>Akeso, AstraZeneca, HARMONi, HARMONi-3, HARMONi-7, Ivonescimab, Summit Therapeutics, United States Food and Drug Administration</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/six-popular-sunscreen-ingredients-face-growing-scrutiny-cs-analytical-sees-a-testing-opportunity/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T13:04:50+00:00</news:publication_date>
      <news:title>Six popular sunscreen ingredients face growing scrutiny. CS Analytical sees a testing opportunity</news:title>
      <news:keywords>Avobenzone, Clifton, CS Analytical, Homosalate, Octinoxate, Octisalate, Octocrylene, Oxybenzone, Raw Material Analytical, United States Food and Drug Administration</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/eli-lilly-is-building-a-3-5bn-retatrutide-factory-why-will-patients-wait-until-2031/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T13:01:23+00:00</news:publication_date>
      <news:title>Eli Lilly is building a $3.5bn retatrutide factory. Why will patients wait until 2031?</news:title>
      <news:keywords>David Ricks, Edgardo Hernandez, Eli Lilly and Company, Fogelsville, Lehigh Valley, Mounjaro, Pennsylvania, retatrutide, Zepbound</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/braccos-new-ai-can-flag-brain-aneurysms-above-3-mm-can-it-improve-radiology-detection/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T12:57:18+00:00</news:publication_date>
      <news:title>Bracco’s new AI can flag brain aneurysms above 3 mm. Can it improve radiology detection?</news:title>
      <news:keywords>Avicenna.AI, Bracco Group, Bracco Imaging, CINA-Aneurysm, CINA-Aneurysm+, Radiological Society of North America, Subtle Medical, United States Food and Drug Administration, UPTUNITY</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2026/07/Median-Technologies-and-Olea-Medical-partner-to-commercialise-eyonis-LCS-lung-cancer-screening-AI-e1785513560404.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/htl-biotechnology-is-betting-e15m-on-salmon-derived-dna-can-regenerative-medicine-justify-the-expansion/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T12:54:10+00:00</news:publication_date>
      <news:title>HTL Biotechnology is betting €15m on salmon-derived DNA. Can regenerative medicine justify the expansion?</news:title>
      <news:keywords>Brittany, France, François Fournier, HTL Biotechnology, HTL Biotechnology Innovation, HTL8, Javené</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2026/05/AVLs-science-backed-skincare-push-raises-a-bigger-question-about-beauty-and-biotechnology-e1779025288209.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/novo-nordisk-cut-sickle-cell-crises-by-27-could-etavopivat-become-its-next-major-medicine/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T12:50:39+00:00</news:publication_date>
      <news:title>Novo Nordisk cut sickle cell crises by 27%. Could etavopivat become its next major medicine?</news:title>
      <news:keywords>Etavopivat, European Medicines Agency, Forma Therapeutics, HIBISCUS, HIBISCUS2, Novo Nordisk, United States Food and Drug Administration</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2026/07/Laboratory-researchers-e1784822111116.webp</image:loc>
    </image:image>
  </url>
</urlset>